Age, Adiposity-Related Anthropometrics, and Clinical Outcomes in Heart Failure with Mildly Reduced or Preserved Ejection Fraction: A Participant-Level Pooled Analysis of Randomized Trials
Abstract Body (Do not enter title and authors here): Background: Age has been shown to modify the population-level association between body mass index (BMI) and mortality. However, whether age modifies the association between adiposity-related anthropometrics and adverse outcomes in heart failure (HF) populations has not been systematically explored.
Methods: In this participant-level pooled analysis of five international, multicenter, randomized-controlled trials enrolling adults with HF and either mildly reduced or preserved ejection fraction (HFmrEF/HFpEF), the association between age and adiposity-related anthropometrics (BMI, waist circumference [WC], and waist-to-height ratio [WHtR]) and the primary composite outcome of time-to-first HF hospitalization or cardiovascular (CV) death was evaluated using multivariable adjusted Cox proportional hazards models (stratified by treatment and trial) and restricted cubic splines.
Results: Among 21,606 participants in the analysis (mean age, 71±9 years; 49% female; 83% White; mean BMI, 30±6 kg/m2), 5,350 (25%) were aged <65 years, 8,273 (38%) were aged 65-74 years, and 7,983 (37%) were aged ≥75 years at baseline. Older individuals were more likely to be female, have lower BMI and WC, and higher left ventricular ejection fraction. Overall, BMI, WC, and WHtR were steeply and non-linearly associated with the primary outcome (Figure). Age, as either a categorical or continuous variable, significantly modified the covariate-adjusted association between all anthropometrics and the primary composite outcome (P≤0.001 for all) (Figure). A J-shaped relationship, characterized by higher incidence of the primary outcome with lower anthropometric values, was observed only for BMI and was substantially attenuated among younger adults. Irrespective of the anthropometric used, increasing adiposity was most steeply associated with primary events among adults aged <65 years.
Conclusions: In this pooled analysis of HFmrEF/HFpEF trials, age was a powerful modifier of the relationship between excess adiposity and HF hospitalization or CV death. An “obesity-survival paradox” – observed only for BMI – was not apparent in younger participants, who exhibited the steepest increase in the rate of clinical events with higher adiposity.
Ostrominski, John
( Brigham and Womens Hospital
, Boston
, Massachusetts
, United States
)
Pitt, Bertram
( University of Michigan School
, Ann Arbor
, Michigan
, United States
)
Zannad, Faiez
( CVCT and Universite de Lorraine
, Paris
, France
)
Zile, Michael
( MEDICAL UNIV OF SOUTH CAROLINA
, Charleston
, South Carolina
, United States
)
Mcmurray, John
( BHF CARDIOVASCULAR RESEARCH CENTRE
, Glasgow
, United Kingdom
)
Solomon, Scott
( Brigham and Women's Hospital
, Boston
, Massachusetts
, United States
)
Vaduganathan, Muthiah
( Brigham and Womens Hospital
, Boston
, Massachusetts
, United States
)
Claggett, Brian
( Brigham and Women's Hospital
, Boston
, Massachusetts
, United States
)
Anand, Inder
( VA SAN DIEGO HEATHCARE SYSTEM
, La Jolla
, California
, United States
)
Desai, Akshay
( BRIGHAM WOMENS HOSPITAL
, Boston
, Massachusetts
, United States
)
Jhund, Pardeep
( UNIVERSITY OF GLASGOW
, Glasgow
, United Kingdom
)
Lam, Carolyn
( NATIONAL HEART CENTRE SINGAPORE
, Singapore
, Singapore
)
Pfeffer, Marc
( BRIGHAM and WOMENS HOSPITAL
, Boston
, Massachusetts
, United States
)
Author Disclosures:
John Ostrominski:DO NOT have relevant financial relationships
| Bertram Pitt:No Answer
| Faiez ZANNAD:DO have relevant financial relationships
;
Advisor:NovoNordisk:Past (completed)
; Advisor:Northsea:Expected (by end of conference)
; Advisor:Merck:Active (exists now)
; Advisor:CEVA:Past (completed)
; Advisor:Cellprothera:Active (exists now)
; Advisor:Cereno:Active (exists now)
; Ownership Interest:CVCT:Active (exists now)
; Advisor:Cardior:Past (completed)
; Advisor:CVRx:Active (exists now)
; Advisor:BMS:Past (completed)
; Advisor:Boehringer:Active (exists now)
; Advisor:Biopeutics:Active (exists now)
; Consultant:Owkin:Active (exists now)
; Advisor:Bayer:Active (exists now)
; Advisor:Applied Therapeutics:Past (completed)
| Michael Zile:DO NOT have relevant financial relationships
| John McMurray:DO have relevant financial relationships
;
Research Funding (PI or named investigator):British Heart Foundation, National Institute for Health – National Heart Lung and Blood Institute (NIH-NHLBI), Boehringer Ingelheim, SQ Innovations, Catalyze Group. - Payment to Glasgow University:Active (exists now)
; Other (please indicate in the box next to the company name):KBP Biosciences - My employer, Glasgow University, has been paid by KBP Biosciences for my time spent scientific advisor to company to help guide clinical development in cardio-renal disease, inflammation & infection.:Past (completed)
; Consultant:WIRB-Copernicus Group Clinical Inc. - Data Safety Monitoring Board:Active (exists now)
; Other (please indicate in the box next to the company name):Bayer - My employer, Glasgow University, has been paid by Bayer for my time spent as Steering Committee member for the PANACHE trial using neladenoson bialanate and for the FINEARTS trial with finerenone. These payments were made through a Consultancy with Glasgow University and I have not received personal payments in relation to these trials/drugs.:Active (exists now)
; Other (please indicate in the box next to the company name):Glaxo Smith Kline - My employer, Glasgow University, has been paid by GSK for my time spent as Co-principal investigator and Steering Committee member, respectively, for the Harmony-Outcomes trial (albiglutide) and two trials, ASCEND-D and ASCEND-ND, using daprodustat, and meetings related to these trials. GSK has also paid my travel and accommodation for some of these meetings. These payments were made through a Consultancy with Glasgow University and I have not received personal payments in relation to these trials/drugs.:Active (exists now)
; Other (please indicate in the box next to the company name):Novartis - My employer, Glasgow University, has been paid by Novartis for my time spent as Executive Committee member and then co-principal investigator of ATMOSPHERE, co-principal investigator of the PARADIGM-HF and PARAGON-HF trials and Executive/Steering Committee member for PARADISE-MI, PERSPECTIVE and PARACHUTE-HF trials (with sacubitril/valsartan) and meetings/presentations related to these trials and aliskiren and sacubitril/valsartan. Novartis has also paid my travel and accommodation for some of these meetings. These payments were made through a Consultancy with Glasgow University and I have not received personal payments from Novartis in relation to these trials/drugs.:Active (exists now)
; Other (please indicate in the box next to the company name):Cardurion - My employer, Glasgow University, has been paid by Cardurion for my participation in a company advisory board about development of a PDE 9 inhibitor in heart failure.:Active (exists now)
; Consultant:Global Clinical Trial Partners Ltd. - Director:Active (exists now)
; Consultant:Alynylam Pharmaceuticals, Amgen, AnaCardio, AstraZeneca, Bayer, Berlin Cures, BMS, Cardurion, Cytokinetics, Ionis Pharmaceuticals, Novartis, Regeneron Pharmaceuticals, River 2 Renal Corp.:Active (exists now)
; Other (please indicate in the box next to the company name):Theracos - My employer, Glasgow University, has been paid by Theracos for my time spent as Principal investigator for the BEST trial and meetings related to this trial. Theracos has also paid my travel and accommodation for some of these meetings. These payments were made through a Consultancy with Glasgow University and I have not received personal payments in relation to this trial/this drug.:Past (completed)
; Other (please indicate in the box next to the company name):Amgen - My employer, Glasgow University, has been paid by Amgen for my time spent as Steering Committee member for the ATOMIC-HF, COSMIC-HF and GALACTIC-HF trials and meetings and other activities related to these trials. Amgen has also paid my travel and accommodation for some of these meetings/activities. These payments were made through a Consultancy with Glasgow University and I have not received personal payments in relation to these trials/this drug.:Active (exists now)
; Other (please indicate in the box next to the company name):Cytokinetics - My employer, Glasgow University, has been paid by Cytokinetics for my time spent as Steering Committee member for the ATOMIC-HF, COSMIC-HF and GALACTIC-HF trials and meetings and other activities related to these trials. Cytokinetics has also paid my travel and accommodation for some of these meetings/activities. These payments were made through a Consultancy with Glasgow University and I have not received personal payments in relation to these trials/this drug.:Active (exists now)
; Speaker:Abbott, Alkem Metabolics, Astra Zeneca, Blue Ocean Scientific Solutions Ltd., Boehringer Ingelheim, Canadian Medical and Surgical Knowledge, Emcure Pharmaceuticals Ltd., Eris Lifesciences, European Academy of CME, Hikma Pharmaceuticals, Imagica Health, Intas Pharmaceuticals, J.B. Chemicals & Pharmaceuticals Ltd., Lupin Pharmaceuticals, Medscape/Heart.Org., ProAdWise Communications, Radcliffe Cardiology, Sun Pharmaceuticals, The Corpus, Translation Research Group, Translational Medicine Academy - personal lecture fees:Active (exists now)
; Other (please indicate in the box next to the company name):AstraZeneca - My employer, Glasgow University, has been paid by AstraZeneca (who market dapagliflozin) for my time spent as Principal Investigator of DAPA-HF and Co-principal Investigator of DELIVER and DETERMINE (trials using dapagliflozin) in heart failure and meetings and other activities related to these trials. AstraZeneca has also paid my travel and accommodation for these meetings. These payments were made through a Consultancy with Glasgow University and I have not received personal payments in relation to this trial/this drug.:Active (exists now)
| Scott Solomon:DO have relevant financial relationships
;
Research Funding (PI or named investigator):Alexion, Alnylam, Applied Therapeutics, AstraZeneca, Bellerophon, Bayer, BMS, Boston Scientific, Cytokinetics, Edgewise, Eidos/BridgeBio, Gossamer, GSK, Ionis, Lilly,NIH/NHLBI, Novartis, NovoNordisk, Respicardia, Sanofi Pasteur, Tenaya, Theracos, US2.AI:Active (exists now)
; Consultant:Abbott, Action, Akros, Alexion, Alnylam, Amgen, Arena, AstraZeneca, Bayer, BMS, Cardior, Cardurion, Corvia, Cytokinetics, GSK, Intellia, Lilly, Novartis, Roche, Theracos, Quantum Genomics, Tenaya, Sanofi-Pasteur, Dinaqor, Tremeau, CellProThera, Moderna, American Regent, Sarepta, Lexicon, Anacardio, Akros, Valo:Active (exists now)
| Muthiah Vaduganathan:DO have relevant financial relationships
;
Researcher:received research grant support, served on advisory boards, or had speaker engagements with American Regent, Amgen, AstraZeneca, Bayer AG, Baxter Healthcare, BMS, Boehringer Ingelheim, Chiesi, Cytokinetics, Lexicon Pharmaceuticals, Merck, Novartis, Novo Nordisk, Pharmacosmos, Relypsa, Roche Diagnostics, Sanofi, and Tricog Health, and participates on clinical trial committees for studies sponsored by AstraZeneca, Galmed, Novartis, Bayer AG, Occlutech, and Impulse Dynamics:Active (exists now)
| Mats Lassen:DO NOT have relevant financial relationships
| Jawad Butt:DO have relevant financial relationships
;
Researcher:AstraZeneca:Past (completed)
; Researcher:Bayer:Past (completed)
| Brian Claggett:DO have relevant financial relationships
;
Consultant:Cardior:Active (exists now)
; Consultant:Eli Lilly:Active (exists now)
; Consultant:CVRx:Past (completed)
; Consultant:Intellia:Active (exists now)
; Consultant:Cytokinetics:Past (completed)
; Consultant:Cardurion:Active (exists now)
| Inder Anand:DO NOT have relevant financial relationships
| Akshay Desai:DO have relevant financial relationships
;
Research Funding (PI or named investigator):Abbott:Active (exists now)
; Individual Stocks/Stock Options:DTX plus:Past (completed)
; Consultant:Veristat, Zydus:Past (completed)
; Consultant:Medpace, Porter Health, Regeneron, River2Renal, Roche, Verily:Active (exists now)
; Consultant:Merck, Medtronic, Parexel, scPharmaceuticals:Past (completed)
; Consultant:Bayer, Biofourmis, Novartis:Active (exists now)
; Consultant:Avidity, Axon Therapeutics, Boston Scientific, GlaxoSmithKline:Past (completed)
; Consultant:Abbott, Alnylam, AstraZeneca:Active (exists now)
; Research Funding (PI or named investigator):Pfizer:Active (exists now)
; Research Funding (PI or named investigator):Novartis:Active (exists now)
; Research Funding (PI or named investigator):Bayer:Active (exists now)
; Research Funding (PI or named investigator):AstraZeneca:Active (exists now)
; Research Funding (PI or named investigator):Alnylam:Active (exists now)
| Pardeep Jhund:DO have relevant financial relationships
;
Speaker:Novartis:Past (completed)
; Speaker:ProAdwise Communications:Past (completed)
; Research Funding (PI or named investigator):Roche Diagnostics:Active (exists now)
; Research Funding (PI or named investigator):Analog Devices Inc:Active (exists now)
; Research Funding (PI or named investigator):AstraZeneca:Past (completed)
; Speaker:Intas Pharmaceuticals:Past (completed)
; Speaker:Sun Pharmaceuticals:Past (completed)
; Other (please indicate in the box next to the company name):Novo Nordisk - clinical trial work:Active (exists now)
; Other (please indicate in the box next to the company name):Bayer - clinical trial work:Active (exists now)
; Other (please indicate in the box next to the company name):Astrazeneca - clinical trial work:Active (exists now)
; Other (please indicate in the box next to the company name):Novartis - clinical trial work:Past (completed)
; Speaker:AstraZeneca:Past (completed)
; Advisor:Novartis:Past (completed)
| Carolyn Lam:DO have relevant financial relationships
;
Consultant:Alleviant Pharma, Allysta Pharma:Active (exists now)
; Other (please indicate in the box next to the company name):Us2.ai (Co-founder & Non-Executive Director):Active (exists now)
; Research Funding (PI or named investigator):Novo Nordisk, Roche Diagnostics:Active (exists now)
; Consultant:Siemens Healthcare, Us2.ai:Active (exists now)
; Consultant:ReCor Medical, Roche Diagnostics, Sanofi:Active (exists now)
; Consultant:Prosciento Inc, Quidel Corporation, Radcliffe Group:Active (exists now)
; Consultant:Medscape, Merck, Novartis, Novo Nordisk:Active (exists now)
; Consultant:Ionis Pharmaceutical, Janssen R&D LLC:Active (exists now)
; Consultant:Impulse Dynamics, Intellia Therapeutics:Active (exists now)
; Consultant:CPC Clinical Research, Eli Lilly:Active (exists now)
; Consultant:Boston Scientific, Bristol Myers Squibb:Active (exists now)
; Consultant:Biopeutics, Boehringer Ingelheim:Active (exists now)
; Consultant:Astra Zeneca, Bayer:Active (exists now)
; Consultant:AnaCardio, Applied Therapeutics:Active (exists now)
| Marc Pfeffer:DO have relevant financial relationships
;
Consultant:Alexion, Alnylam, Apnimed, AstraZeneca, Boehringer Ingelheim and Eli Lilly Alliance, DalCor, Intellia, Novartis, and Novo Nordisk. :Active (exists now)
; Individual Stocks/Stock Options:Dal-Cor:Active (exists now)
; Researcher:Lexicon, Novartis:Past (completed)